ReviewCardiorenal medicine2013
Dyslipidemia in patients with chronic and end-stage kidney disease.
Review in Cardiorenal medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 30 citations in OpenAlex.
- Trial
- Butyrate-Mediated Modulation of Paraoxonase-1 Alleviates Cardiorenometabolic Abnormalities in a Rat Model of Polycystic Ovarian Syndrome.Cardiovascular drugs and therapy · 2025Article
- Does metabolic syndrome increase contrast-induced nephropathy in patients with normal renal function?Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2024Article
- Novel oxidized LDL-based clinical markers in peritoneal dialysis patients for atherosclerosis risk assessment.Redox biology · 2023Article
- Lipid status association with 25-hydroxy vitamin D: Cross sectional study of end stage renal disease patients.Journal of medical biochemistry · 2020Article
- Dyslipidemia and Intraperitoneal Inflammation Axis in Peritoneal Dialysis Patients: A Cross-Sectional Pilot Study.Kidney diseases (Basel, Switzerland) · 2020Article
- The impact of dyslipidemia and oxidative stress on vasoactive mediators in patients with renal dysfunction.International urology and nephrology · 2019Review
- Association between Dyslipidemia and Peritoneal Dialysis Technique Survival.Open access Macedonian journal of medical sciences · 2019Article
- Metabolic Syndrome and the Iodine-Dose/Creatinine Clearance Ratio as Determinants of Contrast-Induced Acute Kidney Injury.Cardiorenal medicine · 2018Article
- Effects of dyslipidaemia on monocyte production and function in cardiovascular disease.Nature reviews. Cardiology · 2017Review
- Dyslipidemia in patients with chronic kidney disease: etiology and management.International journal of nephrology and renovascular disease · 2017Review
- Oxidized Low-Density Lipoprotein Predicts the Development of Renal Dysfunction in Atrial Fibrillation.Cardiorenal medicine · 2016Article
- Impact of metabolic syndrome on development of contrast-induced nephropathy after elective percutaneous coronary intervention among nondiabetic patients.Clinical cardiology · 2015Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we discuss the physiology, diagnosis and treatment of dyslipidemia in patients with chronic and end-stage renal disease. The recent important clinical trials in patients with chronic kidney disease and dyslipidemia are reviewed. Because of the lack of evidence in treating lipid abnormalities in this specific patient population, we propose that future studies should focus on the pathophysiological mechanisms and treatment of dyslipidemia in this special patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.